The International Telecom Community Awarded Nexign Microservices Platform Twice in a Week
26.10.2021 10:00:00 EEST | Business Wire | Press release
Nexign (part of ICS Holding), an international provider of business support systems (BSS), has announced it won the MEA Technology Achievement Award and was shortlisted for another prestigious international award for the telecom industry, Glotel.
The MEA Tech Award was introduced by the MEA Business magazine, one of the business's top publications in the Middle East and Africa, while the Global Telecom Award brings together the top players in telecom from around the world recognizing innovation and excellence.
The prize and the nomination were awarded the same week for the Nexign Microservices Platform and the Microservices Factory project based on it.
Nexign Microservices Platform supports the whole cycle of development and delivery based on cloud-native microservices architecture, which lays the foundation for continuous creation of new digital services. The framework leverages CI/CD automation and facilitates partner collaboration through standardised APIs. This solution enabled the launch of Microservices Factory at MegaFon and allowed the company to reduce TTM for internal innovations. Nexign Microservices Framework empowered MegaFon to roll out 100+ new services, bring to market a multi-subscription digital services platform MegaFon Plus, and generally slash TTM from 3-4 months up to 2 weeks.
The project resulted in building the Open Ecosystem, constantly expanding with the new partners enriching MegaFon’s portfolio with the new product offerings. Nexign Microservices Platform enables telecom operators to always stay at the forefront of market changes and steadily cater to the ever-changing needs of its customers.
Both the development project and the final product have garnered recognition from the international telecom industry, to which the MEA Tech Award and the Glotel nomination are a token.
“The award and the nomination are not just a huge honour for Nexign. They signify the professional community’s recognition and appreciation of our projects. We strongly believe the Microservices Platform is a solution the world of telecom really needs these days. It would allow CSPs to swiftly react to any challenges the market can throw at them,” says Dmitry Antipov, the Customer Relations Director at Nexign.
About Nexign
Nexign (a part of Intellectual Computer Systems Holding (ICS Holding) is a major supplier of BSS solutions for telecom operators across 17 countries. The company focuses on modernising CSP’s IT systems to boost their profitability and slash TTM for new products.
Over 30 years on the market, Nexign has created an extensive suite of technological solutions to support and sustain transformation of telecom operators. Nexign’s products range from convergent BSS systems to elaborate optimisation solutions for subordinate software. Nexign boasts its comprehensive approach to reorganising all kinds of processes in the telecom industry, which offers a fresh impetus to the customer business and encourages innovations.
For more information, please visit the website and follow the latest news from Nexign on Twitter, Facebook and LinkedIn.
About ICS Holding
Intellectual Computer Systems Holding (https://x-holding.ru/) is a multidisciplinary Russian IT group, which holds a leading position in the technology and IT services development market. ICS Holding is the largest IT provider for telecom operators and one of the fastest growing IT holdings in the Russian market. ICS Holding is among Russia’s top three largest IT development companies, top ten IT companies and top ten suppliers of equipment for the industrial sector. The holding brings together more than 30 companies united in five subholdings: YADRO, Nexign, Citadel, Kryptonit and Forpost.
ICS Holding’s top priorities include the digital transformation of enterprise companies, information security, data storage systems, cryptography and quantum computing, machine learning and artificial neural networks, blockchain technology and artificial intelligence (AI). In terms of geographical reach, the business covers all regions of Russia, as well as several countries in the CIS and further afield.
ICS Holding companies employ in excess of 6,000 people. More than 120 global projects have been implemented in Russia and worldwide. More than 1000 of ICS Holding’s customers work in more than 20 countries.
The total revenue of ICS Holding companies in 2020 reached 85 billion rubles. The partner network of ICS Holding includes more than 50 companies in Russia and beyond.
15.09.2020 ICS Holding became a part of USM Telecom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005212/en/
Contact information
Galiya Sayfutdinova
Marketing Communications Team Lead, Nexign
galiya.sayfutdinova@nexign.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom